JPRN-UMIN000006620招募中未知
Randomized phase II study of maintenance pemetrexed, bevacizumab, and pemetrexed+bevacizumab after induction chemotherapy with carboplatin+pemetrexed in advanced nonsquamous NSCLC. - Randomized phase II study of maintenance PEM, BEV, and PEM+BEV
Kyoto Thoracic Oncology Research Group0 个研究点目标入组 99 人开始时间: 2012年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Induction chemotherapy 1.severe comorbit disease 2.history of hemoptysis, coagulation disorder and thrombosis 3.tumor cavitation 4.invasion to the major vessel 5.myocardial infarction or brain infarction within 6 months 6.pregnant or lactating woman 7.brain metastasis with high risk of bleeding 8.interstitial pneumonia 9.effusion needed drainage 10.surgery within 4 weeks 11.radiation within 4 weeks 12.drainage within 1 week 13.double cancer Maintenance chemotherapy 1)PD after induction chemotherapy 2)hemoptysis 3)bleeding tendency or thrombosis 4)ECOG PS 2-4
研究者
相似试验
已完成
不适用
A randomized phase 2 study of maintenance pemetrexed versus docetaxel following pemetrexed plus carboplatin in advanced non-small cell lung cancerJPRN-UMIN000004075Hamamatsu University School of Medicine84
已完成
不适用
Phase II study of pemetrexed maintenance with or without bevacizumab after a first line treatment chemotherapy with bevacizumab-carboplatin-pemetrexed in patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000010002Internal Medicine 2, Hamamatsu University School of Medicine.110
进行中（未招募）
不适用
Maintenance in elderly patient advanced Lung CancerEUCTR2012-005520-15-FRIFCT
尚未招募
不适用
A prospective study comparing targeted anticancer drug + irinotecan and targeted anticancer drug + 5-Fluorouracil / Leucovorin as maintenance treatment after primary induction chemotherapy for metastatic colorectal cancerNeoplasmsKCT0008619ational Cancer Center138
进行中（未招募）
不适用
PHASE II STUDY FOR METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FOLFOXIRI AND BEVACIZUMAB AND THEN TREATED WITH BEVACIZUMAB OR WITH BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPYMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006332-23-ITARCO